Posts tagged “Biotech & Life Science”

August 15, 2007

Premium Lock Class Action Complaint ‘Completely Without Merit,’ Pozen Says

Pozen Three law firms have announced suits against Pozen after FDA rejected drug.

August 15, 2007

Premium Lock Campbell Alliance Opens Office in Atlanta

Raleigh-based consulting firm has added four offices in past year.

August 15, 2007

Premium Lock NC Health Information Group Unveils Mobile Security Template

NCHICA Document spells out procedures, policies for protecting health information.

Updated August 14, 2007

Premium Lock Icagen Lands Potential $1 Billion Deal with Pfizer

Icagen Update: Drug giant to invest up to $15M in Icagen stock. Development of three products could produce $359M each. Pfizer also makes $12M upfront payment.

August 13, 2007

Premium Lock Inspire Launches Sale of Eye Treatment Drug

Inspire Durham company licensed rights to AzaSite for $32 million.

August 13, 2007

Premium Lock FDA Rejects Solvay-Wyeth Drug Targeting Schizophrenia

FDA Companies plan to continue to seek approval of bifeprunox.

August 9, 2007

Premium Lock Trimeris Reports Another Profit, But Stock Falls 11% in After-Hours Trading

Trimeris Major stockholder requests meeting with management. Trimeris also discloses plans to advance HIV drug candidate to clinical trials.

Updated August 9, 2007

Premium Lock N.C. Biotech Center Awards $822,000 in Grants to 11 Scientists

Biotech Center Grant program is designed to help researchers move toward commercialization of discoveries.

August 8, 2007

Premium Lock Inspire Shares Jump 9% on Earnings News

Inspire Company’s revenues and size of losses top Street expectations.

August 8, 2007

Premium Lock FDA Rejects GSK Bid for New Dosage of Emphysema Drug

GlaxoSmithKline Setback is second in less than two weeks for a big-selling GSK product. FDA recently required stronger warnings on GSK diabetes drug.

Updated August 8, 2007

Premium Lock Trimeris Extends Contracts with Several Top Executives

Trimeris Interim president hired in March could stay in place through 2008 at $450 per hour.

August 2, 2007

Premium Lock Duke Establishes Center for Study of Systems Biology

DNA UniversityTech: $14.5M federal grant launches program at Duke Institute for Genome Sciences & Policy. Researchers will study how biological networks govern living cells over minutes, days – and millions of years.

Updated August 2, 2007

Premium Lock FDA Delays Pozen-GSK Migraine Drug; Pozen Shares Dive

Trexima pills delayed. (Pozen photo) Concerns focus on data from genotoxicity test. Pozen CEO says new data will be gathered quickly.

Updated August 2, 2007

Premium Lock No Decision From FDA on Pozen - GSK Migraine Drug

Trexima pills receive FDA approval. (Pozen photo) A decision from the FDA may come nearly two months after Pozen disclosed two trials demonstrating the efficacy of its proposed migraine drug Trexima.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith